



Edgar Filing: CorMedix Inc. - Form 8-K

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.



Item 5.07.

Submission of Matters to a Vote of Security Holders.

The Company's 2018 annual meeting of stockholders was held on December 11, 2018. At the meeting, stockholders elected the following six members to the Company's Board of Directors for a term expiring at the annual meeting of stockholders in 2019, based on the following votes:

| Member           | For        | Withheld  | Broker<br>Non-Votes |
|------------------|------------|-----------|---------------------|
| Khoso Baluch     | 17,078,603 | 3,399,817 | 61,188,542          |
| Janet Dillione   | 18,911,474 | 1,566,946 | 61,188,542          |
| Gary Gelbfish    | 19,603,724 | 874,696   | 61,188,542          |
| Myron Kaplan     | 17,707,417 | 2,771,003 | 61,188,542          |
| Mehmood Khan     | 18,847,399 | 1,631,021 | 61,188,542          |
| Steven Lefkowitz | 19,667,027 | 811,393   | 61,188,542          |

Also, at the meeting, stockholders approved on a non-binding advisory basis the Company's executive compensation. The vote for such approval was 17,269,019 shares for, 2,931,056 shares against, 278,345 shares abstaining and 61,188,542 broker non-votes.

Finally, at the meeting, stockholders also ratified the appointment of Friedman LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2018. The vote for such approval was 80,445,413 shares for, 862,828 shares against, 358,721 shares abstaining and no broker non-votes.



SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

CORMEDIX INC.

Date: December 11, 2018 By: /s/ Robert W. Cook  
Name Robert W Cook  
Title Chief Financial Officer